Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) has earned an average rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month target price among […]
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on April 28,... | April 28, 2023
Adicet Bio, Inc. (NASDAQ:ACET – Get Rating)’s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $11.53 and traded as low as $5.47. Adicet Bio shares last traded at $5.64, with a volume of 339,197 shares changing hands. Analyst Ratings Changes Several research […]
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive... | April 13, 2023
Eleven healthcare-focused companies have been named the best small-cap companies of 2023 by Forbes.